Millendo Therapeutics (NASDAQ:MLND) Cut to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Millendo Therapeutics (NASDAQ:MLND) from a hold rating to a sell rating in a report published on Wednesday, Zacks.com reports.

According to Zacks, “Millendo Therapeutics Inc. is a biopharmaceutical company. It focuses on developing novel treatments for orphan endocrine diseases. The company’s product candidate consists of AZP-531 and ATR-101 which are in clinical stage. Millendo Therapeutics Inc., formerly known as OvaScience Inc., is based in Ann Arbor, United States. “

A number of other research analysts have also weighed in on the stock. Jefferies Financial Group began coverage on shares of Millendo Therapeutics in a research note on Wednesday, March 13th. They issued a buy rating and a $22.00 price target on the stock. ValuEngine lowered shares of Welbilt from a hold rating to a sell rating in a research note on Wednesday, June 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $23.25.

Shares of Millendo Therapeutics stock opened at $10.67 on Wednesday. Millendo Therapeutics has a twelve month low of $6.77 and a twelve month high of $17.34. The company has a 50-day moving average of $13.36. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.83 and a current ratio of 7.83.

Millendo Therapeutics (NASDAQ:MLND) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.08). Sell-side analysts forecast that Millendo Therapeutics will post -3.25 EPS for the current year.

A number of institutional investors have recently modified their holdings of MLND. Geode Capital Management LLC purchased a new position in Millendo Therapeutics in the 4th quarter worth approximately $113,000. BlackRock Inc. purchased a new position in Millendo Therapeutics in the 4th quarter worth approximately $203,000. Worth Venture Partners LLC purchased a new position in Millendo Therapeutics in the 4th quarter worth approximately $206,000. Private Advisors LLC lifted its stake in Millendo Therapeutics by 9.1% in the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock worth $229,000 after purchasing an additional 1,279 shares in the last quarter. Finally, Tibra Equities Europe Ltd purchased a new position in Millendo Therapeutics in the 1st quarter worth approximately $303,000. 44.07% of the stock is currently owned by hedge funds and other institutional investors.

Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Recommended Story: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on Millendo Therapeutics (MLND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.